Global Menopause Treatment Market, By Treatment Type (Hormone Therapy, Non-hormonal Therapy, Others), By Route of Administration (Oral, Topical, Parenteral, Vaginal, Others), By Form (Tablets, Creams, Patches , Pessaries, Injections, Others), By Indicatio

Global Menopause Treatment Market, By Treatment Type (Hormone Therapy, Non-hormonal Therapy, Others), By Route of Administration (Oral, Topical, Parenteral, Vaginal, Others), By Form (Tablets, Creams, Patches , Pessaries, Injections, Others), By Indication (Perimenopause, Menopause, Postmenopause), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Stores, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

The global menopause treatment market was valued US$ 15.33 Bn in 2023 and is expected to reach US$ 24.33 Bn by 2031 growing at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

Figure 1. Global Menopause Treatment Market Share (%), By Region, 2023

Menopause is a natural biological process that usually occurs between the ages of 45 to 55 years in women. It marks the end of a woman's reproductive years and the transition into her post-reproductive life. Some of the most common signs and symptoms of menopause include irregular menstrual periods, hot flashes, night sweats, vaginal dryness, mood changes, and difficulty sleeping. As menopause progresses, a woman's estrogen levels drop dramatically, which could lead to several long-term health risks if left untreated. Therefore, managing symptoms during this transitional phase has become a priority for many women. The global menopause treatment market offers a variety of treatment options for women suffering from menopause symptoms.

Market Dynamics:

The rising prevalence of menopause issues among women owing to changing lifestyle patterns and growing health awareness levels is a key factor driving the growth of global menopause treatment market. Numerous researches have shown that approximately one-fourth of women within the age group of 40 to 60 years report experiencing at least one problematic symptom associated with menopause. There is also the emergence of sedentary jobs and a lack of physical activity, which has escalated the risks of premature or early menopause. Additionally, new product approvals and launches by leading pharmaceutical players are expanding the treatment choices for addressing vasomotor symptoms during menopause. However, side effects associated with hormone replacement therapy and the availability of alternative treatment options still limit the market potential to a certain extent. Moreover, a lack of awareness about treatment in developing nations poses a challenge to market players. Nonetheless, technological advancements in menopausal care and growing medical tourism in the Asia Pacific region are expected to unlock lucrative opportunities for stakeholders in coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global menopause treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global menopause treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novo Nordisk A/S, illendo Therapeutics, Inc., Mithra Pharmaceuticals, Merck & Co., Inc, Cipla Inc., Abbott, Viatris Inc., Organon, SnapNurse, Glenmark Pharmaceuticals Limited, Procter & Gamble, Duchesnay USA., TherapeuticsMD, Inc., Avion Pharmaceuticals, KWS, PharmaCare Europe Ltd., Amneal Pharmaceuticals LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global menopause treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global menopause treatment market

Detailed Segmentation:

• Global Menopause Treatment Market, By Treatment Type
• Hormone Therapy

 Estrogen-based Drugs

 Progestin-based Drugs

 Combination Drugs (Estrogen and Progestin, Estrogen and Other Medicines)

• Non-hormonal Therapy

 Neurokinin 3 (NK3)

 Receptor Antagonist

 Selective Serotonin

 Reuptake Inhibitor (SSRI)

 Others

• Others
• Global Menopause Treatment Market, By Route of Administration
• Oral
• Topical
• Parenteral
• Vaginal
• Others
• Global Menopause Treatment Market, By Form
• Tablets
• Creams
• Patches
• Pessaries
• Injections
• Others
• Global Menopause Treatment Market, By Indication
• Perimenopause
• Menopause
• Postmenopause
• Global Menopause Treatment Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Stores
• Others
• Global Menopause Treatment Market, By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Top Companies in the Global Menopause Treatment Market:
• Novartis AG
• Pfizer Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Novo Nordisk A/S
• illendo Therapeutics, Inc.
• Mithra Pharmaceuticals
• Merck & Co., Inc
• Cipla Inc.
• Abbott
• Viatris Inc.
• Organon
• Glenmark Pharmaceuticals Limited
• Procter & Gamble
• Duchesnay USA.
• TherapeuticsMD, Inc.
• Avion Pharmaceuticals
• KWS
• PharmaCare Europe Ltd.
• Amneal Pharmaceuticals LLC.